{"id":12977,"date":"2026-08-28T16:50:13","date_gmt":"2026-08-28T16:50:13","guid":{"rendered":"https:\/\/facesconsent.com\/blog\/?p=12977"},"modified":"2026-08-28T16:54:23","modified_gmt":"2026-08-28T16:54:23","slug":"yellow-card-reporting-for-aesthetic-practitioners","status":"publish","type":"post","link":"https:\/\/facesconsent.com\/blog\/yellow-card-reporting-for-aesthetic-practitioners\/","title":{"rendered":"Yellow Card Reporting for Aesthetic Practitioners"},"content":{"rendered":"\n

Practitioners offering botulinum toxin treatments<\/mark><\/a> and dermal fillers<\/mark><\/a> sit at the only point in the chain where an adverse reaction is seen early enough to matter. What aesthetic clinics<\/mark><\/a> <\/mark>notice in the fortnight after treatment is what the regulator either finds out about or never hears. That gap between the treatment room and the MHRA is the reason the reporting system exists at all.<\/p>\n\n\n\n

In June 2025, nine patients arrived at two hospitals in North East England with drooping eyelids, slurred speech and difficulty swallowing. The alert that started the investigation came from A&E, not from the treatment rooms. By the time UKHSA closed the count in August, 41 clinically confirmed cases of iatrogenic botulism had been recorded across five English regions. Seized product from the outbreak investigation into cosmetic botulinum neurotoxin injections<\/mark><\/a> tested at 370 units per vial against a label claiming 200. What follows is what to report, when, and what the MHRA does with it once you have.<\/p>\n\n\n\n

What the Yellow Card Scheme Covers in Aesthetic Practice<\/h2>\n\n\n\n

The yellow card scheme is the MHRA’s route for collecting suspected safety problems with any healthcare product on the UK market. It takes reports on suspected adverse drug reactions to medicines and vaccines, adverse incidents involving medical devices, medicines that are not of acceptable quality, and falsified or fake products. For aesthetics, that covers almost everything in the treatment room.<\/p>\n\n\n\n

Two points matter more than the rest.<\/p>\n\n\n\n

Anyone can report. <\/strong>There is no professional register you need to be on, no employer sign-off, no clinical qualification threshold. Non-medic injectors, clinic managers, the receptionist fielding the phone call and patients themselves can all submit. Given that a large share of UK injectors sit outside GMC, NMC, GDC and GPhC registration and therefore carry no professional reporting duty at all, this open access is much of what holds the dataset together.<\/p>\n\n\n\n

You do not have to prove causality.<\/strong> The MHRA guidance on what to report<\/mark><\/a> states that only a suspicion is needed. Practitioners talk themselves out of reporting because they cannot rule out patient factors, technique or a coincidental illness. Working out which of those it was is the regulator’s job. Submitting is not an admission that the product caused the reaction, and it is not an admission of error.<\/p>\n\n\n\n

\"Aesthetic<\/figure>\n\n\n\n

Toxins and fillers take different routes<\/h3>\n\n\n\n

Botulinum toxin type A<\/mark><\/a> is a prescription-only medicine, so a reaction to it is an adverse drug reaction. Dermal fillers are regulated as medical devices, so a problem with one is an adverse incident. Both go through the same Yellow Card reporting website<\/mark><\/a>, on different forms with different fields.<\/p>\n\n\n\n

The device route has a rule that catches people out. Do not throw the product away, and do not attempt to clean or repair it. Keep the syringe, vial, outer packaging and batch labelling. If police or a coroner become involved, hold the item until the MHRA contacts you. Do not post anything to the MHRA unless you are specifically asked.<\/p>\n\n\n\n

Geography changes the route for device incidents. In England, Wales and Northern Ireland, report to the Yellow Card scheme. Northern Ireland moved across on 1 August 2025 when the Northern Ireland Adverse Incident Centre closed its reporting function. In Scotland, device incidents go to Health Facilities Scotland, unless you are a private facility treating private clients, in which case you report to the MHRA and the Care Inspectorate.<\/p>\n\n\n\n

When to Submit a Yellow Card Report After Treatment<\/h2>\n\n\n\n

For an established medicine, submit a yellow card report for every serious suspected reaction, even where the effect is already well recognised. Serious has a defined meaning here: fatal, life-threatening, resulting in a congenital abnormality, disabling or incapacitating, or resulting in or prolonging hospitalisation. A patient admitted overnight for observation after unexpected dysphagia meets that bar. Ptosis that settles over three weeks does not, though it is still worth reporting if anything about the presentation was unusual for the dose and placement used.<\/p>\n\n\n\n

Products carrying an inverted black triangle are the exception. These sit under additional monitoring, typically for the first five years after authorisation or following a major safety review, and every suspected reaction should be reported regardless of severity. Several of the newer ready-to-use neuromodulators on the UK market carry it. Check the summary of product characteristics on the electronic medicines compendium rather than assuming a product has come off additional monitoring. The symbol appears immediately after the product name.<\/p>\n\n\n\n

Report a defective or falsified product even when no patient was harmed. A vial that looks wrong, a carton with inconsistent printing, a leaflet in the wrong language, a product that behaves nothing like it should at the dose you always use: all of that goes through the falsified medicines and devices reporting route. The MHRA’s Criminal Enforcement Unit acts on this material, and several investigations into unlicensed toxin supply were opened following the 2025 hospital admissions.<\/p>\n\n\n\n

The four-week tail<\/h3>\n\n\n\n

The MHRA Drug Safety Update on iatrogenic botulism<\/mark><\/a>, published in July 2026, puts onset at typically four to eight days, but up to four weeks after treatment. Risk rises with high doses, with off-label use and administration into unapproved sites, in patients with underlying neurological disorders or a history of dysphagia or aspiration, and with counterfeit or unauthorised products. Neck work is worth singling out on that list, since treating platysma bands with botulinum toxin<\/mark><\/a> sits outside the licensed indications for every UK-authorised type A product.<\/p>\n\n\n\n

The practical consequence is that a patient who rings on day 18 about swallowing is inside the window, not outside it. Severe eyelid droop, breathing difficulty, slurred speech and muscle weakness after treatment are a medical emergency first: the patient needs immediate medical help, and the report follows. Full detail on the consent and aftercare changes that update prompted is in the piece on MHRA’s updated botulism warning and what to change in clinic<\/mark><\/a>.<\/p>\n\n\n\n

How the MHRA Yellow Card System Handles Your Submission<\/h2>\n\n\n\n

The MHRA yellow card system accepts reports through the website, the free Yellow Card app, and several clinical IT systems including EMIS, SystmOne, Vision, MiDatabank, Ulysses, Cerner and Medicus. Paper reports go by FREEPOST YELLOW CARD with no other address needed, or by email to yellowcard@mhra.gov.uk<\/mark><\/a>. Patients without online access can call 0800 731 6789 free, Monday to Friday, 9am to 5pm. Device incidents cannot be reported by telephone at all; patients without online access email aic@mhra.gov.uk<\/mark><\/a> instead.<\/p>\n\n\n\n

Once submitted, reports feed signal detection. The MHRA reviews them alongside clinical trial data, literature and reports from other regulators, and acts when a pattern emerges. The strengthened product information published across all UK-authorised type A toxins in 2026 is the visible output of exactly that process. You can see what has already been reported for a substance through the interactive drug analysis profiles<\/mark><\/a>, which list every suspected reaction reported in the UK for a given drug.<\/p>\n\n\n\n

Those profiles also show the scale of the problem. An <\/mark>MHRA freedom of information response on cosmetic botulinum toxin reports<\/mark><\/a> put the cumulative total at 396 UK spontaneous suspected adverse drug reaction reports for botulinum toxin used cosmetically, up to 27 July 2023. The MHRA added its own caveat: indication is not a mandatory field, so the true figure could be higher. Set against the number of toxin treatments carried out in the UK over the same period, 396 is a thin dataset on which to base national safety decisions. Every report that does not get filed makes it thinner.<\/p>\n\n\n\n

Yellow Card MHRA Reporting Sits Alongside Other Duties<\/h2>\n\n\n\n

Filing a yellow card MHRA submission does not discharge anything else you owe. Three obligations run in parallel and get confused with each other regularly.<\/p>\n\n\n\n

Botulism is a notifiable disease in England. Clinicians must report suspected cases to UKHSA, and that duty is entirely separate from the Yellow Card. In the 2025 outbreak it was the notifiable disease route, not pharmacovigilance reporting, that triggered the multi-agency investigation.<\/p>\n\n\n\n

GMC-registered doctors have explicit obligations. The GMC guidance for doctors who offer cosmetic interventions<\/mark><\/a> requires them to report product safety concerns to the relevant regulator and to tell patients how to report complications and adverse reactions themselves. Prescribers who authorise administration by another person carry responsibility for making sure that person understands the product information and safety guidance.<\/p>\n\n\n\n

Your insurer is a third, separate notification. A Yellow Card is not a claim notification, and a claim notification is not a Yellow Card. Check the notification clause in your aesthetic insurance cover<\/mark><\/a>, because most policies set a window measured in days from the point you become aware of a potential claim.<\/p>\n\n\n\n

Nothing statutory yet compels a non-medic injector to do any of this. Section 180 of the Health and Care Act 2022 gives ministers the power to license non-surgical cosmetic procedures in England, and the Department of Health and Social Care confirmed a three-tier risk model in its August 2025 consultation response, but no regulations have been made and no commencement date is set. The House of Commons Library briefing on the regulation of non-surgical cosmetic procedures in England<\/mark><\/a> sets out where the scheme currently stands. Until it lands, reporting discipline in most of the sector rests on voluntary practice.<\/p>\n\n\n\n

Telling the patient how to report<\/strong><\/h3>\n\n\n\n

Patients can and should file their own reports, and the fact that they can is meaningful: a patient describing what they felt at week two adds detail no practitioner observation captures. Very few are ever told the option exists. Adding a line to your digital aftercare forms<\/mark><\/a> with the reporting website and the app name takes one edit and closes that gap permanently. Reference it again in your <\/mark>digital consent forms for aesthetic treatments<\/mark><\/a> so it is documented before treatment as well as after.<\/p>\n\n\n\n

Building MHRA Yellow Card Reporting Into Clinic Workflow<\/h2>\n\n\n\n

An MHRA yellow card is only as useful as the detail attached to it, and most of that detail has to be captured at the time of treatment rather than reconstructed a fortnight later. Record the full product name and strength, the batch or lot number, the expiry date, the dose in units per injection point, the dilution used if applicable, injection sites and depths, the treatment date and time, concomitant medicines, and relevant medical history. When a reaction is reported, add onset timing and what you did in response.<\/p>\n\n\n\n

Keep the packaging until the episode is closed. A batch number recalled from memory is worth very little to an investigation, and it is the single field most often missing from reports.<\/p>\n\n\n\n

Two things worth building in beyond the record-keeping. The free MHRA adverse drug reaction e-learning module<\/mark><\/a> runs to about 45 minutes and carries one hour of CPD, which logs neatly into a CPD portfolio<\/mark><\/a> <\/mark>and covers the reporting thresholds better than any internal briefing will. And since counterfeit and unlicensed stock is the risk factor the MHRA has been loudest about, sourcing through a regulated route matters more than it used to. Buying from an online pharmacy UK for aesthetic products<\/mark><\/a> with a named prescriber attached to the order gives you a batch trail you can actually follow back, and practitioners without prescribing rights can find an aesthetic prescriber<\/mark><\/a> through the same platform.<\/p>\n\n\n\n

\"Practitioner<\/figure>\n\n\n\n

Get a Second Opinion Before the Report, Not After<\/h2>\n\n\n\n

Reporting is what happens after a complication has been recognised. The harder part is the twenty minutes before that, when a patient is in front of you with a presentation you have not seen before and you need a clinical steer immediately. Faces members can reach the 24\/7 aesthetic complications helpline<\/mark><\/a> for \u00a39 per month, which puts a trained medical professional on the phone at any hour, on any day, for medics and non-medics alike. Advice comes by phone, email or video call, so you can show the presentation rather than describe it.<\/p>\n\n\n\n

If you are treating with toxin and have no escalation route mapped out beyond NHS 111, add Complications Consultant telephone support<\/mark><\/a> to your setup before the next clinic day rather than during it.<\/p>\n\n\n\n

FAQs<\/h2>\n\n\n
\n
\n
\n

What is the Yellow Card scheme?<\/strong><\/p>\n

\n\n

It is the MHRA’s national system for collecting reports of suspected safety problems with medicines, vaccines, medical devices, blood products and e-cigarettes in the UK. Reports come from healthcare professionals, patients and the public, and the MHRA uses them to detect safety signals and to update product information, warnings and licensing where the evidence supports it.<\/p>\n\n<\/div>\n<\/div>\n

\n

Who can submit a Yellow Card report?<\/strong><\/p>\n

\n\n

Anyone. There is no requirement to be a registered healthcare professional, and non-medic aesthetic practitioners, clinic staff and patients can all submit directly through the website or the app. You do not need the patient’s consent to report, and you do not need to be the person who administered the treatment.<\/p>\n\n<\/div>\n<\/div>\n

\n

Do dermal filler complications need to be reported to the MHRA?<\/strong><\/p>\n

\n\n

Yes, through the medical device adverse incident route rather than the drug reaction route, because fillers are regulated as devices rather than medicines. Report vascular occlusion, delayed-onset nodules, granulomas, infection and any product that behaved unexpectedly, and retain the syringe and packaging rather than disposing of them.<\/p>\n\n<\/div>\n<\/div>\n

\n

How long after treatment can you report a reaction?<\/strong><\/p>\n

\n\n

There is no deadline. Report as soon as you become aware of a suspected reaction, including reactions that present weeks after treatment, and including historic cases you did not report at the time. Late reports still contribute to the safety picture, and for botulinum toxin the MHRA specifically flags an onset window extending to four weeks.<\/p>\n\n<\/div>\n<\/div>\n

\n

What happens after you submit a report?<\/strong><\/p>\n

\n\n

The MHRA assesses the report and adds it to its safety database, where it is analysed alongside other reports for the same product. Individual reports are not usually acknowledged with a clinical response, and the scheme cannot give medical advice, so a patient needing clinical input should be directed to their GP, NHS 111 or emergency care depending on severity. Where a pattern emerges, the MHRA can update product information, issue a Drug Safety Update, restrict use or suspend a licence.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Practitioners offering botulinum toxin treatments and dermal fillers sit at the only point in the chain where an adverse reaction is seen early enough to matter. What aesthetic clinics notice in the fortnight after treatment is what the regulator either finds out about or never hears. That gap between the treatment room and the MHRA […]<\/p>\n","protected":false},"author":6,"featured_media":12981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[20],"tags":[12,9,10,227],"class_list":["post-12977","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aesthetics","tag-aesthetics","tag-dermal-fillers","tag-medical-practitioners","tag-uk"],"_links":{"self":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/comments?post=12977"}],"version-history":[{"count":2,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12977\/revisions"}],"predecessor-version":[{"id":12983,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12977\/revisions\/12983"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/media\/12981"}],"wp:attachment":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/media?parent=12977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/categories?post=12977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/tags?post=12977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}